[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100276607":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":19,"locations":19,"responsibleParty":24,"collaborators":19,"id":27,"slug":28,"hasResults":29,"nctId":30,"briefTitle":31,"officialTitle":32,"acronym":19,"eligibilityCriteria":33,"healthyVolunteers":29,"sex":34,"minAge":35,"maxAge":19,"enrollmentInfo":36,"targetDuration":19,"studyType":39,"phases":40,"briefSummary":42,"conditions":43,"keywords":19,"overallStatus":45,"whyStopped":19,"lastUpdateSubmitDate":46,"lastUpdatePostDateStruct":47,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":19},{"fullName":5,"class":6},"Chaohu Hospital of Anhui Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"proximal femoral nail antirotation","EXPERIMENTAL","Twenty patients with intertrochanteric femoral fracture scheduled will undergo proximal femoral nail antirotation (PFNA) implantation.",[13],"Device: proximal femoral nail antirotation",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DEVICE","Twenty patients with intertrochanteric femoral fracture scheduled to undergo proximal femoral nail antirotation (PFNA) implantation.",[9],null,[21],{"name":22,"affiliation":5,"role":23},"Junjie Xu, MD","PRINCIPAL_INVESTIGATOR",{"type":23,"investigatorFullName":25,"investigatorTitle":26,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"Junjie Xu","Associate Chief Physician","100276607","safety-and-effectiveness-of-proximal-femoral-nail-antirotation-for-the-treatment-of-intertrochanteric-femoral-fracture-100276607",false,"NCT02880501","Safety and Effectiveness of Proximal Femoral Nail Antirotation for the Treatment of Intertrochanteric Femoral Fracture","Safety and Effectiveness of Proximal Femoral Nail Antirotation for the Treatment of Intertrochanteric Femoral Fracture: Study Protocol for a Prospective Case Series","Inclusion Criteria:\n\n* Intertrochanteric femoral fracture diagnosed by anterior-posterior and lateral X-ray images, CT and MRI scans\n* Types II-IV intertrochanteric femoral fracture in Evans-Jensen classification (Fung et al., 2007)\n* Osteoporosis-caused intertrochanteric femoral fracture\n* Fresh closed fracture (surgery performed within 2 weeks after fracture)\n* Surgery performed for the first time after fracture\n* Healthy and able to tolerance to anesthesia and surgery\n* Age \\>18 years\n* Provision of informed consent about participation and trial procedure\n\nExclusion Criteria:\n\n* Not suitable to undergo internal fixation (such as severe osteoarthritis, rheumatoid arthritis and pathological fracture)\n* Has installed other auxiliary devices in injured hip joint\n* Infection of tissue around the hip joint\n* With bone metabolism disorders besides osteoporosis, such as renal osteodystrophy and osteomalacia\n* With heart, lung, brain and other systemic diseases\n* With advanced malignant tumor\n* Recently suffering from cerebral hemorrhage, myocardial infarction, and failure of important organs which are difficult to be corrected\n* With injured limb deep venous thrombosis\n* With mental disorders\n* Unable to tolerance to surgery","ALL","18 Years",{"count":37,"type":38},20,"ESTIMATED","INTERVENTIONAL",[41],"NA","Minimally invasive PFNA fixation for the treatment of intertrochanteric femoral fracture will be used in 20 patients within 2 years to objectively validate the safety and effectiveness of PFNA in the treatment of fracture of long tube-like bone.",[44],"Intertrochanteric Femoral Fracture","UNKNOWN","2016-08-23",{"date":48,"type":38},"2016-08-26",{"date":50,"type":19},"2015-01",{"date":52,"type":38},"2016-12",{"name":5,"class":6}]